These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 8026989)

  • 1. Effect of single amino acid substitution at residue 167 of HLA-B51 on binding of antibodies and recognition of T cells.
    Nakayama S; Kawaguchi G; Karaki S; Nagao T; Uchida H; Kashiwase K; Akaza T; Nasuno T; Takiguchi M
    Hum Immunol; 1994 Mar; 39(3):211-9. PubMed ID: 8026989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discrimination of HLA-B5 crossreactive group antigens by human allospecific CTL clones.
    Matsumoto K; Yamamoto J; Hiraiwa M; Kano K; Takiguchi M
    Transplantation; 1990 Jun; 49(6):1164-7. PubMed ID: 2360256
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crucial role of N-terminal residue of binding peptides in recognition of the monoclonal antibody specific for the peptide-HLA-B5, -B35 complex.
    Sakaguchi T; Takamiya Y; Edidin M; Nokihara K; Miwa K; Schönbach C; Takiguchi M
    Immunogenetics; 1998; 47(2):149-58. PubMed ID: 9396861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allodeterminants and evolution of a novel HLA-B5 CREG antigen, HLA-B SNA.
    Sekimata M; Hiraiwa M; Andrien M; Dupont E; Karaki S; Yamamoto J; Kano K; Takiguchi M
    J Immunol; 1990 Apr; 144(8):3228-33. PubMed ID: 1691230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of the conserved residue in pocket A and the polymorphic residue in pocket E of HLA-B*3501 in presentation of human minor histocompatibility peptides to T cells.
    Takiguchi M; Kawaguchi G; Sekimata M; Hiraiwa M; Kariyone A; Takamiya Y
    Int Immunol; 1994 Sep; 6(9):1345-52. PubMed ID: 7819142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of nonamer peptides to three HLA-B51 molecules which differ by a single amino acid substitution in the A-pocket.
    Kikuchi A; Sakaguchi T; Miwa K; Takamiya Y; Rammensee HG; Kaneko Y; Takiguchi M
    Immunogenetics; 1996; 43(5):268-76. PubMed ID: 9110930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T cell can recognize the allospecificities formed by the substitution of amino acids associated with HLA-Bw4/Bw6 public epitopes.
    Hiraiwa M; Yamamoto J; Matsumoto K; Karaki S; Nagao T; Kano K; Takiguchi M
    Hum Immunol; 1991 Sep; 32(1):41-5. PubMed ID: 1723061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the substitutions in the alpha helix and the beta sheet of HLA class I molecule on allorecognition of T cells specific for HLA-B51 and HLA-Bw53.
    Hiraiwa M; Nishimura I; Kato N; Nagao T; Kano K; Takiguchi M
    Hum Immunol; 1992 Feb; 33(2):82-8. PubMed ID: 1373416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polymorphism of human minor histocompatibility antigens: T cell recognition of human minor histocompatibility peptides presented by HLA-B35 subtype molecules.
    Beck Y; Satz L; Takamiya Y; Nakayama S; Ling L; Ishikawa Y; Nagao T; Uchida H; Tokunaga K; Müller C
    J Exp Med; 1995 Jun; 181(6):2037-48. PubMed ID: 7759996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presentation of human minor histocompatibility antigens by HLA-B35 and HLA-B38 molecules.
    Yamamoto J; Kariyone A; Akiyama N; Kano K; Takiguchi M
    Proc Natl Acad Sci U S A; 1990 Apr; 87(7):2583-7. PubMed ID: 2157206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The HLA-A,B "negative" mutant cell line C1R expresses a novel HLA-B35 allele, which also has a point mutation in the translation initiation codon.
    Zemmour J; Little AM; Schendel DJ; Parham P
    J Immunol; 1992 Mar; 148(6):1941-8. PubMed ID: 1541831
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A panel of unique HLA-A2 mutant molecules define epitopes recognized by HLA-A2-specific antibodies and cytotoxic T lymphocytes.
    Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
    J Immunol; 1989 Mar; 142(6):2097-104. PubMed ID: 2466083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Residue 116 determines the C-terminal anchor residue of HLA-B*3501 and -B*5101 binding peptides but does not explain the general affinity difference.
    Kubo H; Ikeda-Moore Y; Kikuchi A; Miwa K; Nokihara K; Schönbach C; Takiguchi M
    Immunogenetics; 1998; 47(3):256-63. PubMed ID: 9435344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single T cell receptor-mediated recognition of an identical HIV-derived peptide presented by multiple HLA class I molecules.
    Ueno T; Tomiyama H; Takiguchi M
    J Immunol; 2002 Nov; 169(9):4961-9. PubMed ID: 12391209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The structure of HLA-B35 suggests that it is derived from HLA-Bw58 by two genetic mechanisms.
    Ooba T; Hayashi H; Karaki S; Tanabe M; Kano K; Takiguchi M
    Immunogenetics; 1989; 30(2):76-80. PubMed ID: 2788131
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.
    Burrows SR; Silins SL; Khanna R; Burrows JM; Rischmueller M; McCluskey J; Moss DJ
    Eur J Immunol; 1997 Jul; 27(7):1726-36. PubMed ID: 9247584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Two subtypes of HLA-B51 differing by substitution at position 171 of the alpha 2 helix.
    Kawaguchi G; Hildebrand WH; Hiraiwa M; Karaki S; Nagao T; Akiyama N; Uchida H; Kashiwase K; Akaza T; Williams RC
    Immunogenetics; 1992; 37(1):57-63. PubMed ID: 1428012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isolation of a human allo-peptide presented by HLA-B51 molecules.
    Tomiyama H; Takamiya Y; Hill AB; Cerundolo V; Kelly A; Egawa K; Trowsdale J; Takiguchi M
    Int Immunol; 1995 Jun; 7(6):905-9. PubMed ID: 7577798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification by site-directed mutagenesis of amino acid residues contributing to serologic and CTL-defined epitope differences between HLA-A2.1 and HLA-A2.3.
    Hogan KT; Clayberger C; Bernhard EJ; Walk SF; Ridge JP; Parham P; Krensky AM; Engelhard VH
    J Immunol; 1988 Oct; 141(7):2519-25. PubMed ID: 2459215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytotoxic T cell recognition of allelic variants of HLA B35 bound to an Epstein-Barr virus epitope: influence of peptide conformation and TCR-peptide interaction.
    Khanna R; Silins SL; Weng Z; Gatchell D; Burrows SR; Cooper L
    Eur J Immunol; 1999 May; 29(5):1587-97. PubMed ID: 10359113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.